Table III.
Summary of antitumor response.
| Variable | Total number of patients (n=94) | Patients with grade 3 or 4 neutropenia within the first cycle of treatment (n=26) | Patients without grade 3 or 4 neutropenia within the first cycle of treatment (n=68) | P-value |
|---|---|---|---|---|
| Best overall response, n (%) | ||||
| Complete response | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Partial response | 0 (0.0) | 0 (0.0) | 0 (0.0) | – |
| Stable disease | 42 (44.7) | 16 (61.5) | 26 (38.2) | – |
| Progressive disease | 45 (47.9) | 10 (38.5) | 35 (51.5) | – |
| Not evaluated | 7 (7.4) | 0 (0.0) | 7 (10.3) | – |
| Disease control rate, % | 42 (44.7) | 16 (61.5) | 26 (38.2) | 0.07 |
-, not available.